Advanced Therapies: Clinical, Non-clinical and Quality Considerations

4Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Cell therapy, tissue engineering, and gene therapy products, together called “advanced therapy medicinal products” (ATMPs), represent a heterogeneous group of innovative biopharmaceuticals. ATMPs are based on viable cells, tissue, or genetic material. In this chapter, after a brief introduction, first different classification systems of these products are discussed, illustrated with representative examples of products in clinical development or commercially available. Next, the challenges associated with successful pharmaceutical development, manufacturing, and testing of these products are covered. Finally, regulatory aspects are dealt with.

Cite

CITATION STYLE

APA

Hoogendoorn, K. H. (2019). Advanced Therapies: Clinical, Non-clinical and Quality Considerations. In Pharmaceutical Biotechnology: Fundamentals and Applications (pp. 357–402). Springer International Publishing. https://doi.org/10.1007/978-3-030-00710-2_17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free